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1Chapter
Human Papillomavirus Infection: 
Management and Treatment
Suchibrata Das
Abstract
Human papillomavirus infections are very common and recurrent. Their presen-
tation varies according to their site of affection. Spontaneous recovery is common in 
a good number of patients. An ideal wart therapy resolves all or maximum number 
of warts, is painless, needs only one or a part of a wart treated, needs only minimum 
number of treatments, leaves no scar, offers lifetime HPV immunity and is easily 
available for all patients. Various modalities of treatment are available—from some 
folk and alternative therapies to destructive, antimitotic, virucidal, immunotherapy 
and combination of therapies. In every modality, the result is significant. Younger 
individuals with short duration of illness usually have the highest clearance rates for 
various treatments. Recurrence rate is also high in almost every treatment modality. 
Immunotherapy has a promising role.
Keywords: human papillomavirus infection, chemical cautery, electrocautery, 
cryotherapy, laser therapy, immunotherapy
1. Introduction
Human papillomaviruses (HPVs) are a large and diverse group of viruses with 174 
completely characterised types, with new HPV types being continuously found [1]. 
There are five major HPV genera: Alphapapillomavirus, Betapapillomavirus, Gamma 
papillomavirus, Mu papillomavirus and Nu papillomavirus. HPVs infect epithelial 
cells in genital mucosa (Alphapapillomaviruses only), oral mucosa or skin (repre-
sentatives of all five genera). The most common clinical manifestation is verruca, 
with different morphological forms. The histology shows acanthosis, elongation of 
dermal papillae, presence of vacuolated cells and koilocytes. Subclinical manifesta-
tions are invisible to the human eye. These subclinical lesions are flat and multiple. 
Their clinical insignificance facilitates their spread, and in women their persistence 
is possibly related to genital cancer.
2. Diagnosis
2.1 Clinical diagnosis
The clinical picture of cutaneous warts differs by specific location on the 
body [2]. Most extragenital warts are benign, and usually clinical diagnosis is 
adequate, but sometimes additional methods are required especially in atypical, 
subclinical or dysplastic lesions. Genital lesions are more prone to transform to 
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malignancy, so determining the extent of disease is essential. Examining the wart 
and scraping off the top layer of the wart to check for signs of dark, pinpoint dots—
clotted blood vessels—are common with warts.
2.2 Dermatoscopy
Warts can be visualised exceptionally well by dermoscopy, especially the 
black dots. Dermoscopy is also very useful in terms of differential diagnosis and 
follow-up [2].
2.3 Acetowhitening
Genital/mucosal lesions remain undetected for a long time; not only that, all 
lesions may not be clinically evident at a time. Topical application of 3–5% of acetic 
acid for 3–5 min and followed by examination with 10X hand lens or colposcope 
is a reasonable accurate diagnostic tool. Lesions will be represented as tiny white 
papules. The routine use of this procedure to detect mucosal changes attributed to 
HPV infection is not recommended because the results do not influence clinical 
management.
3. Laboratory investigations
3.1 Histology
Acanthosis, epidermal hyperplasia, papillomatosis, compact orthokeratosis, 
hypergranulosis, tortuous dermal papillary capillaries, and vertical tiers of para-
keratotic cells are the typical histological findings of warts. In the granular layer, 
cells have coarse keratohyalin granules and vacuoles surrounding wrinkled-
appearing nuclei. Koilocytes are pathognomonic.
3.2  Immunohistochemistry or immunocytochemistry using type-common  
and type-specific antibodies
3.2.1 DNA in situ hybridization
In situ hybridization is a direct signal detection assay. It preserves the morpho-
logical context with HPV DNA signals. It has low sensitivity; however, in recent 
years, using improved signal-detecting method, sensitivity increased. It is becom-
ing a valuable screening tool for women of age more than 30 years.
3.3  Polymer-based enzyme-linked immunosorbent assay (ELISA) for 
immunoglobulin G (IgG) antibody (Ab) against HPV 16 capsid
3.3.1 PCR for HPV DNA
Patients who are diagnosed with condylomata need a Papanicolaou (Pap) 
test of the cervix in accordance with the guidelines of the American College of 
Obstetricians and Gynaecologists
Computed tomography (CT) or magnetic resonance imaging (MRI) can be used 
to determine the extent of spread of cervical carcinoma and extensive anogenital 
papillomatosis that has spread into the pelvis.
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4. Treatment
Warts are usually self-limiting. Large studies have shown complete spontane-
ous remission in 42% of patients after 2 months; in 53%, after 6 months; and in 
65%, after 2 years [2]. The intact immune system plays the most important role for 
preventing HPV infection. This can be seen in patients with primary immunodefi-
ciency or in immunosuppressed patients.
HPV-induced warts are the most common skin disorder in organ transplant 
recipients [3]. Children with recalcitrant extragenital wart may suffer from primary 
immunodeficiency. It has been shown that immunosuppressed patients experience 
resolution of treatment-refractory warts once their immune status has improved [4]. 
The known spontaneous remission of HPV-induced warts, which is attributed to cell-
bound mechanisms, underscores the role of the immune system, including an increase 
in Th1 cytokines and infiltration of T cells (CD4+, CD8+) around the diseased tissue [5].
Guidelines for the management of cutaneous warts have been prepared for 
dermatologists on behalf of the British Association of Dermatologists [6]. The 
guideline highlighted the ideal aims of treatment of warts as follows: (i) Removal of 
wart without recurrence. (ii) Treatment should result with no scars. (iii) Immunity 
that induced by treatment should be lifelong [5]. The general principles observed 
in the treatment of warts are the following: (1) There is no need to treat all warts. 
(2) Treatment indications are pain, interference with function, cosmetic embar-
rassment and risk of malignancy. (3) All the treatments have success rate not very 
high (average 60 ± 70% clearance in 3 months). (4) An immune response is usually 
essential for clearance. Immunocompromised individuals may never show wart 
clearance. (5) Younger individuals with short duration of illness usually have the 
highest clearance rates for various treatments [5].
There is a high rate of spontaneous remission, especially in children, so ‘wait-and-
see’ approach is feasible in many cases. Regular filing or paring down the hyperkera-
totic layer makes the lesion thin and comfortable. Simple measure to limit the spread 
of lesion should be encouraged. The treatment of warts can be broadly classified into 
destructive, antimitotic, virucidal, immunotherapy, and some folk and alternative 
therapies which have recently become popular again.
The goals of wart treatment are to resolve all or a maximum number of warts, 
make it painless, need only one or a part of a wart treated, only need minimum 
number of treatments, leave no scar, offer lifetime HPV immunity and be easily 
available for all patients [7]. The criteria for wart treatment, developed by the 
American Academy of Dermatology in 1995, [7] include (1) the patient’s desire 
for therapy; (2) symptoms of pain, bleeding, itching or burning; (3) disabling or 
disfiguring lesions; (4) large numbers or large sizes of lesions; (5) the patient’s 
desire to prevent the spread of warts to unblemished skin of self or others; and (6) 
an immunocompromised condition [6].
4.1 Destructive therapy
The lesions are damaged or removed by different procedures followed by clinical 
cure. The destructive therapies include surgical removal by curettage and cautery, 
chemical cautery, cantharidin, cryotherapy, electrocautery, radiocautery ablation, 
infrared coagulation, photodynamic therapy, and lasers.
4.1.1 Surgery
Curettage followed by cautery was an early and still widely practiced method of 
surgical removal of warts. A success rate of 65–85% has been reported in surgical 
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therapy, but scarring and recurrence rate are high (30%), and the sole of the foot is 
the site where scarring is particularly problematic. Curettage followed by cautery is 
most commonly used for filiform warts on the limbs and face [8]. Excision is usually 
to be avoided as scarring is inevitable, and there is frequent chance of recurrence in 
the scar.
4.2 Salicylic acid
It is keratolytic, reduces the thickness of warts and may also stimulate an inflam-
matory response. Over-the-counter preparations are available as 17% salicylic acid 
combined in a base of flexible collodion or as a 40% salicylic acid plaster patch [9]. 
It is minimally expensive, convenient and reasonably effective, with negligible pain, 
but results require weeks to months of treatment. Occasionally, contact dermatitis 
due to colophony may develop, and to avoid systemic toxicity, it should be applied 
only in limited area. Treatment result with salicylic acid therapy extremely depends 
on patient compliance. Before pairing or debridement of the dead, hyperkeratotic 
tissue, wart(s) should be soaked in warm water for 5 min. The salicylic acid prepa-
ration should then be applied to the debrided wart [10].
4.3 Chemical cautery
Strong chemicals can destroy tissue. Trichloroacetic acid (TCA) and bichloro-
acetic acid (BCA) are not readily absorbed by tissue; it kills warts by denaturing 
and destroying the proteins in the cells. Treatment via chemical cautery with a 
solution of 60–90% trichloroacetic acid (TCA) is most effective when treating 
few small, moist lesions. There is a complete clearance of warts in 70% of patients 
who received up to 6 treatments of trichloroacetic acid. Thirty percent of patients 
who were treated with trichloroacetic acid developed ulcerations at the site of its 
application [11]. Recurrence rate is not clear. Silver nitrate is probably most widely 
recognised in its historical use to prevent conjunctivitis in newborns [12]. This 
treatment for warts is currently more widely used in the United Kingdom where 
non-prescription 95% silver nitrate caustic applicator pencils are available [13]. 
Chances of excessive burn and pigmentation are there.
4.4 Cantharidin
A terpenoid secreted by blister beetles, which is absorbed by lipids in kerati-
nocytes, activates serine proteases and leads to acantholysis [14, 15]. Depending 
on the amount, concentration, duration of exposure and occlusion, an intraepi-
dermal blister will form and resolve, within a week [16]. The superficial nature 
of the injury reduces the risk of scarring. One randomised control trial shows 
that cantharidin is effective, is safe, yields better cosmesis and requires fewer 
applications than TCA for the treatment of warts when used sufficiently far 
from mucosal and intertriginous areas. It was also shown to be well tolerated and 
that patients being treated with Cantharone were significantly more satisfied 
than those treated with TCA. This may be attributed to less pain during applica-
tion and during the entire treatment, better cosmetic results and perhaps fewer 
visits [17].
4.5 Phenol (carbolic acid)
It is a strong caustic agent that can penetrate deep into tissue, produces chemical 
burn with escher and is not used routinely for treatment of common wart.  
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Strong (80%) phenol solution for the treatment of common warts showed that 
phenol was an effective form of treatment for warts. It must be used by a physician 
and should not be used in extensive areas [18].
4.6 Retinoic acid
Topical tretinoin, although currently recommended for the treatment of acne, 
has also been reported to be of benefit in plane warts. A study of 25 children 
with plane warts treated with 0.05% topical tretinoin cream (applied once daily 
for 6 weeks) was compared with a control group of 25 untreated children. After 
12 weeks, clearance of warts was observed in 84.6% of the treated group as com-
pared with 32% of the control group. It was well tolerated with some redness and 
peeling in 42.3% of the treated group [19].
4.7 Photodynamic therapy
Photodynamic therapy (PDT) with topical 5-aminolevulinic acid has a good 
curative effect, especially in recalcitrant facial flat warts [20–22]. It is unclear, but 
selective photothermolysis of oxyhaemoglobin within the dilated microvasculature 
of the warts leads to destruction of capillaries followed by improvement of warts, 
may be the mechanism of action of this curative effect [23]. Many factors affect the 
efficacy of PDT, including photosensitizer concentration; solvent type; incubation 
time; type, dose, and time of irradiation of the light; and the area of exposed parts. 
ALA gel (10%) was applied topically to lesions and incubated for 3 h. The lesions 
were irradiated by an LED light of 630 ± 10 nm at dose levels of 60–100 mW/cm. At 
the 24-week follow-up, the average effective rate was 88.8%, with no recurrences. 
No significant side effects were reported [24].
4.8 Cryotherapy
Cryotherapy induces cold thermal injury in the lesion. Cryotherapy may have 
an effect on wart clearance either by simple necrotic destruction of HPV-infected 
keratinocytes or possibly by inducing local inflammation conducive to the develop-
ment of an effective cell-mediated response [25]. Dimethyl ether spray, carbon 
dioxide snow and liquid nitrogen all produce cold thermal damage to the skin. 
Different types of devices and techniques are used to induce targeted cold injury to 
warts. Carbon dioxide slush (−79°C) is now less commonly used.
4.8.1 Mixture of dimethyl ether and propane (DMEP)
It is in aerosol form, easy to handle and stored in normal room temperature, and 
its preservation time is very high (nearly 3 years), available in market and easy to 
buy. As the evaporation temperature reaches −57°, therefore, it is likely to be less 
effective, and efficacy in inducing tissue temperatures adequate for cell necrosis 
appears low [26]. But one multicentre RCT on comparing effects of DMEP and LN2 
shows that no clinically relevant differences between the efficacy, tolerance and 
safety of the two cryogenic agents used in primary care were found. The low freez-
ing of DMEP was sufficient for the cryotherapy of benign lesions [27].
4.8.2 Liquid nitrogen therapy
Having a temperature of −196°C, the coldest freeze, is the most commonly 
used method in medical practice. It is very effective in elimination of a large 
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variety of very common benign and premalignant skin lesions (verrucas, 
Molluscum contagiosum, seborrheic and actinic keratoses) [25]. Wart clearance 
may be through necrotic destruction of HPV-infected keratinocytes or by induc-
ing local inflammation that triggers an effective cell-mediated response [25]. 
Liquid nitrogen can easily be stored and used by simple equipment in clinic-based 
practice. Available techniques are dipstick, roller, spray gun and Probe. Dipstick 
is the simplest technique where a cotton swab is dipped in liquid nitrogen and 
applied on a lesion. It is suitable only for superficial, benign lesions. Cryoroller, 
whose tip is cylindrical, is dipped in liquid nitrogen and then rolled over the 
lesional area. It acts better in severe acne and hypertrophic scar. The most popular 
method is spray technique using cryoprobes [10]. There are variations in freeze 
times, mode of application and intervals between treatments. Freeze time is the 
time elapsed from start to end of freeze cycle, i.e., from formation of uniform 
ice field until lesion is thawed, varying from 5 to 20 s. In short freeze for warts, 
cryotherapy continued till a 2-mm white halo develops around the lesion; this is 
enough for plane wart or filiform warts. But long freeze time (maintaining white 
halo for 5–20 s) is required for plantar warts. The cycle is repeated every 3 weeks 
on 8–10 occasions. It is better to pare hyperkeratotic lesions before cryosurgery as 
it acts as insulator. A cure rate of 60–80% can be anticipated [28]. Longer freeze 
is more effective than traditional (shorter) freeze, and blistering is significantly 
greater [29]. Plantar warts need comparatively more aggressive therapy. There 
is no difference between single freeze-thaw cycle and double freeze-thaw cycle 
in palmer warts but in plantar warts, and double freeze-thaw is more effective 
[30]. The number of session is important, not the interval between sessions for 
percentage cure [31]. Two-week intervals between sessions may be an optimal 
treatment [31].
4.9 Ablation radiofrequency
Localised heating with radiofrequency heat generators and surgical excision 
with radiofrequency electrosurgical knives have been used with moderate success 
[32, 33].
Radiofrequency ablation is a common mode of treatment, and it involves the 
principle of tissue destruction with various waveforms of alternating electric 
current whose frequencies fall within the range of radiofrequency (500–4000 khz) 
[34]. The overall cure rate for warts with radiosurgery ranges between 33 and 80% 
depending on the number of sittings and the type of warts [35, 36].
Electrocautery is a form of electrosurgery that utilises galvanic or direct current 
for generating heat. Although rarely used nowadays in the developed nations, it is 
still widely used in the developing countries and is considered more effective for 
treating thicker lesions with an overall success rate of 56–80% [7].
4.10 Infrared coagulation
It is an instrument that produces noncoherent infrared light with a spectrum 
of 400–2700 nm. It has been reported as a cheaper, safer and more easily handled 
alternative to CO2 laser treatment. Direct application of infrared contact coagula-
tors causes thermal injury to a depth dependent on the duration of exposure [37]. 
A bulla arises after IRC that may protect the lesion against infection. Cure rate was 
66.7% for warts treated with IRC. The instrument allows adjustable tissue necrosis 
without tissue adhesion and has yielded remissions with a 10.8% recurrence rate 
[38]. In comparison to electrocoagulation, infrared coagulation produces similar 
outcomes [37], but it is safer than EC in side effect profile.
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4.11 Laser therapy
4.11.1 Carbon dioxide (CO2) laser
The CO2 laser was the initial laser modality used to treat warts and has been used 
since 1980s [39–41]. The CO2 laser emits infrared light of wavelength 10,600 nm. It 
is absorbed by tissue water and results nonselective thermal tissue destruction. The 
CO2 laser treats warts via two mechanisms. A focused CO2 laser beam used as a scal-
pel to excise the wart down to the subcutaneous tissue, followed by the base of the 
wart, which is vaporised by a defocused beam until a clean surgical field is obtained 
[42–45]. Cohort studies report that simple and recalcitrant common, palmar, plan-
tar, periungual and subungual warts have been successfully treated with CO2 laser, 
with response rates ranging from 50 to 100% [40, 43, 46–53]. Usually, excision by 
focused mode followed by vaporisation and haemostasis with defocused mode is 
the common practice. Deeper warts need more passes. Using two to four passes per 
wart is adequate [46–49]. CO2 laser treatment may be used for recalcitrant warts but 
also as a first-line of therapy for warts—mainly in the sole, hands and other parts 
also [46]. Single verruca lesions usually result better (66.7%) than multiple verruca 
(62.5%) [46]. It can be used for first-line therapy for periungual and subungual 
warts. It has been seen that patients with subungual and periungual warts, who 
have failed previous conventional therapy, respond less than in patients when CO2 
laser therapy was given as first line (47.9% compared to 80.0%) [47]. Subungual 
warts respond better than periungual warts [47]. Usually one or two sessions 
are adequate [48]. Patients with one session heal earlier than patients with more 
than one session [48]. Adverse effects include permanent nail matrix damage and 
scarring, and nail changes such as distal onycholysis and thickening may occur [47, 
48, 51]. CO2 laser may also be used as excision tool, with a remission rate of 95.5%, 
but requires specialised unit [49]. Scarring is a possibility [49]. ‘En bloc’ excision of 
wart is very much effective [100%] in paediatric age group also with no recurrence, 
and usually single session is adequate [50]. Many treatment modalities are not fea-
sible in immunosuppressive patients. CO2 laser can be a safe and comparably effec-
tive modality of treatment, even in one intervention [51]. Complete excision of the 
lesional skin with a portion of deeper tissue and 1-mm non-lesional margin leads to 
the complete clearance of HPV DNA, which leads to very lower recurrence, though 
chance of scar formation is there. Dressing with artificial dermis leads to less scar 
formation [52]. Application of Imiquad after CO2 laser in recalcitrant wart reduces 
or stops recurrences [53]. Vapour produced by CO2 laser with any power density 
and fluence contains intact papillomavirus DNA. This infected vapour may cause 
pulmonary infection [54]. Plume produced from laser procedure collected and used 
as inoculum may produce identical lesions [55]. So, safety precautions during laser 
surgery may be strictly maintained [55]. It is important to wear surgical masks as 
it is capable of removing all laser- or electrocoagulation-derived viruses [56], even 
gas scavenging system to be in use [57]. But a study among CO2 laser surgeons in 
all the members of American Society of Laser Medicine shows that the plume does 
not possess enough infectious material to produce significantly more amount of 
warts in laser surgeons in comparison to population-based common subjects [58]. 
But, sitewise, CO2 laser surgeons have a greater risk of acquiring nasopharyngeal 
lesions, especially when they treat genital warts with HPV types 6 and 11 [58]. 
Scar formation is a known side effect of CO2 lasers, and there are more chances of 
hypertrophic scar formation if the patient is on cyclosporine for other reasons [59]. 
In superpulsed CO2 LASERs, the high irradiances and brief duration make pos-
sible very precise removal of target lesion volumes and controlled excision. Here, 
thermal damage is very less leading to less inflammation and less scarring [60].
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4.11.2 Erbium:yttrium/aluminium/garnet (Er:YAG) laser
Non-ablative lasers are largely replacing ablative CO2 lasers as side effects are 
less, both for patients and clinicians [61]. Er:YAG laser emits 2940 nm wavelength. 
It is absorbed 12–18 times more efficiently by water containing superficial cutane-
ous tissue than CO2 laser. At 250 microsecond pulse duration and 5 J/cm
2 fluence 
short pulse, Er:YAG laser ablates 5–20 micrometre of tissue per laser pass, and 
minimal residual thermal damage that results faster tissue re-epithelialization and 
less side effects. The disadvantage is intraoperative bleeding [62]. Its mechanism 
of action in treating warts is through direct ablation of the lesion in the epidermis, 
layer by layer until normal tissue is visualised. This laser type also has bactericidal 
effects [61]. Er:YAG laser was tried in all types of common warts—periungual, 
subungual and plantar warts; complete clearance rate was 68% for plantar warts, 
78% for periungual warts and 76% for subungual warts. In patients with extensive 
involvement, more than one session were needed. Relapse was only in plantar wart 
patients (17.8%) [62]. Chance of scarring is less in Er:YAG laser [62, 63]. For hard-to-
treat palmoplantar warts, a combination of ablative Er:YAG laser and topical 0.5% 
podophyllotoxin solution yields higher success with complete clearance of 88.6% 
without any pigmentary changes, wound infection and scarring. Relapse rate is also 
less [64]. Er:YAG laser procedure can be done without anaesthesia or with topical 
cream anaesthesia as there is minimal pain, except only in large, very thick plaque 
in the plantar or palm. The plume contains no viral DNA [65]. Side effects are less 
with Er:YAG laser, no hyper- or hypopigmentation and no post-operative infection. 
Healing is very fast, within 7–10 days. Redness persists up to 3 months [66]. In a 
study of 69 patients with difficult-to-treat warts (periungual or plantar), 72.5% of 
patients with wart observed complete response (CR) irrespective of the duration 
of infection with HPV or the age of the patients. Plantar warts were more resistant 
(13.5% non-responders) than periungual warts (5.9% non-responders), and larger 
mosaic plantar warts were less sensitive than single warts; 24.0% of patients showed 
relapse [67]. Wound healing may be assisted/accelerated with LED phototherapy 
(633 nm). Immediately after Er:YAG ablation, with precise removal of wart tissue, a 
red LED therapy system is applied (633 nm, 20 min, 96 J/cm2) to the wound and sur-
rounding area, LED system with same parameters were repeated on the second, sixth 
and tenth post-operative day. On the sixth post-operative day, the wound has shrunk 
noticeably and is filled with healthy, granulation tissue, and on day 15, the wound 
healed completely with minimal scarring; recurrence rate was also less (<6%) [68].
4.11.3 Neodymium:YAG (Nd:YAG) laser
Principal emission of Nd:YAG is at 1064 nm, in the infrared range [Nd:YAG 
produces heat]. Heat therapy depends on the principle that diseased tissue which 
is being treated is more sensitive to the effects of the elevated temperature than 
normal tissue and this is less able to recover after heat exposure [69]. Side effects 
such as coagulation, blister or crusts are less after hyperthermia. Response is 
excellent (77%), though in 23% of the method failed, and there is no recurrence 
in 9 months follow-up. Nd:YAG can be used in all types and site warts including 
periungual, hand and plantar warts [70]. HPV DNA becomes completely absent 
in hyperthermia-treated wart lesions, in comparison to cryotherapy where 96% 
wart lesions are positive for HPV DNA by in situ hybridization [71]. The light of 
the solid state Nd:YAG laser can easily be guided by fibres to tissue and perform 
good coagulation and homeostatic function, in laryngeal, as well as genital, easily 
and more precisely. Its continuous suction endures a minimal load of potential 
infectious laser plume [72]. For therapeutic treatment, Nd:YAG laser can be utilised 
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for genital tract lesion and cervical conization for early neoplasms like dysplasia, 
carcinoma in situ and microinvasive carcinoma [73, 74]; these are caused by HPV 
infections. Invasive lasers like CO2 are normally considerably more painful and 
require longer recovery time, and also side effects like scarring are high. A long 
pulsed Nd:YAG laser emits 1064 nm wavelength light, in infrared spectrum, in 
longer wavelength with lower haemoglobin, and melanin absorption coefficients 
allows deeper delivery of higher energy in hyperkeratotic and thicker epidermis that 
are assisted with warts [75]. Several studies have evaluated the use of the Nd:YAG 
laser in the treatment of simple and recalcitrant common, palmoplantar, periungual 
and subungual warts, with efficacies ranging from 46 to 100% [61, 76–78]. Laser 
protocol varied among different studies: spot size between 3 and 7 mm, pulse 
duration of 1–20 ms, fluence of 100–200 J/cm2, cooling methods, number of pulses 
between 1 and 8, treatment interval from 2 weeks to 12 months and mean number 
of treatments between 1.49 and 4.65. In a study of Han et al. [76], 348 patients of 
all types of simple and recalcitrant common, palmoplantar and periungual warts 
are treated with Nd:YAG laser (spot size, 5 mm; pulse duration, 20 ms; 200 J/cm2; 
no cooling; 1–2 pulses). After a mean of 1.49 treatments, wart clearance rate was 
96% though there were differences in clearance rates after initial treatment depend-
ing on location (72.6% for common warts vs. 44.1% for palmoplantar warts) [76]. 
For determination of effectiveness and safety of a novel 100 microsecond pulsed 
1064 nm Nd:YAG laser in treatment of Verruca vulgaris, low energy (200 mjouls) 
Nd:YAG, in monthly intervals for 3 months was given to 25 patients with lesion on 
hands-nineteen patients had complete clearance; with minimal discomfort [61]. 
At least partial response (50% reduction) in verruca size was noticed in all lesions 
[61]. Aggressive treatment of hand warts may cause tissue damage. To avoid the 
tissue damage, a novel modification was tried [77]. Fifty one recalcitrant verrucas 
were treated with ND:YAG laser; all warts were administered in at least three pulses. 
The circle of pulses given in that way that the three circles overlapped each other 
only on the site of verruca- so that highest level of energy reached only to the wart. 
The adjacent tissue can avoid unintended tissue damage [77]. All lesions subsided, 
88.35% lesions in one laser session, remaining patients were required two laser 
sessions- those lesions were periungual and palmar. There was no recurrence in 12 
months follow-up, no major side effects, no nail dystrophy or severe post-treatment 
scarring. Hyperpigmentation was present in 5.48% patients [77].
4.11.4 Pulsed dye laser
Among non-ablative modalities, pulsed dye laser (PDL) can be used for a 
selective, non-bloody destruction of extragenital and genital warts [79]. It emits 
a wavelength of 585, which is absorbed by haemoglobin and oxyhaemoglobin 
[79, 80]. Mechanism of action is unclear, but may be a result of intense heating of 
dermal vessels that leads to damage of viral DNA-containing keratinocytes. The 
theory is based on the presence of dilated and congested vessels at the base of most 
verruca and the mechanism of selective photothermolysis that results in the target-
ting of haemoglobin by the PDL [80]. The heat and immunological process and the 
removal of the blood supply to the wart may be the reason for the effectiveness of 
PDL in verruca therapy, but it is not above controversy [81]. This selective damage 
to blood vessels, sparing unnecessary damage to healthy adjacent cellular structure, 
avoids the scarring [82]. The local dermal vascular destruction of the warts stimu-
lates cell-mediated immune response that is important for eradication of viral warts 
[83]. So, PDL for wart therapy, even in facial wart, is attractive [84] for its efficient 
and cosmetic resolution [84, 85]. The PDL is usually painless or minimally pain-
ful like snapped by a rubber band [86], though some patients complain of severe 
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intraoperative pain [87, 88], so local anaesthesia may be required. Purpura may 
develop due to sudden burst of wart vasculature—that develops within minutes in 
the treated areas—which takes 10–14 days to subside spontaneously [88]. Even peri-
anal warts in child patients are also treatable with PDL without any complications 
and with 100% clearance [89]. Verruca plana lesions on face in Asian (type IV-V 
skin) clear completely with PDL without producing significant pigmentary and 
textural complications [90]. Safety is one of the major advantages of this technique 
[91]. But the absence of any proven superiority over the standard treatments in 
terms of efficacy, coupled with high costs, means that PDL should only be used as 
second-line therapy in patients with cosmetic needs [91].
Laser protocols are different in all studies, and variation of results may be for that 
reason. Different protocols include spot size of 5–10 mm, fluence of 5 j/m2–15 j/m2, 
pulse duration of 38 ns–1.5 ms, consecutive 2–3 pulses with overlap of 1–2 mm, 1–12 
sessions, interval of 2–4 weeks and cooling methods [90–98]. In immunocompetent 
children, the overall response rate is 75%, and the remaining 25% had partial clear-
ance, with an average number of treatment for complete clearance to be 3.1—face 
and perineum are areas most likely to be cleared in one treatment (50 and 20%, 
respectively) [99, 100]. It is also a more effective therapy especially against those 
that have not been eradicated by other treatments [101]. Though less, adverse effects 
are also not very much uncommon, about 8.2% of patients had adverse effects like 
wound formation (3.8%), residual scarring (2.9%), infection (1.0%) and collapse 
(0.5%); 63% of patients had excessive pain [97]. But opinion about pain and patient 
compliance are different in other study [102]. Here only 6.34% of patients classi-
fied the method as too painful and withdrew after the first one or two treatments 
They have concluded that FPDL is safe and effective for the removal or reduction 
of verrucae vulgares, and requires less patient compliance compared with other 
treatment options. PDL followed by intralesional Bleomycin gives very good result 
with complete clearance, even in immunosuppressive patients, though the overall 
treatment session was high (1.8 vs. 3) [98], but should be aware of common side 
effects seen such as painful haemorrhagic blistering and superficial ulceration [103].
4.11.5 Potassium titanyl phosphate (KTP) laser
The KTP laser has been utilised in the treatment of recalcitrant cutaneous warts, 
and when treated to complete clearance, no recurrence occurred [104].
5. Virucidal therapy
5.1 Glutaraldehyde
Glutaraldehyde is a tissue fixative that polymerises keratin. Its effectiveness lies 
in desiccation of surface virions and resultant reduction of antigenic load [105]. 
However the mechanism of action of glutaraldehyde against warts has not been 
clarified precisely. Glutaraldehyde therapy (GA) for warts was first introduced in 
1971 [106]. Therapeutic responses with glutaraldehyde in periungual, palmar and 
plantar warts were 80, 60 and 68.5%, respectively [107]. When GA is buffered by 
suitable alkalinating agents to a pH of 7.5–8.5, the solution becomes antimicrobially 
active [108]. The concentration of glutaraldehyde is another consideration for use. 
Though 2 w/v% is the minimum for antimicrobial activity [108], undiluted high 
concentration of 25% solution appeared to work faster on warts of all kinds [107]. 
The benefits of using glutaraldehyde as first-line treatment for warts, especially 
resistant ones, are the same as those of cryotherapy [107].
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5.2 Formaldehyde
Formalin (formaldehyde) is a virucidal agent and has strong disinfectant 
properties and exerts its effects by causing damage to the upper layers of epidermal 
cells that contain the virus, thus destroying viruses [28, 109]. Formalin application 
was effective in 83.3% of patients, but complete disappearance of warts was seen in 
11.1% [110]. The most common side effects of formalin include redness, irritation 
and dryness of skin [111].
5.3 Acyclovir, valacyclovir and other antiretroviral drugs
Oral antivirals are not a regular treatment modality, but isolated case report 
about improvement in wart lesion after oral treatment with acyclovir [112], vala-
cyclovir are there. Plantar wart is cleared completely with 1 gm valacyclovir for 
60 days [113]. Improvements of wart with intravenous cidofovir in one HIV sero-
positive patient with complete clearance are available [114]. Nearly total clearance 
of multiple viral wart with didanosine, stavudine and efavirenz triple antiretroviral 
therapy in a 34-year-old male homosexual patient was seen, accompanied by a 
significant improvement in immune status [115]. The observations are not powerful 
enough to assume causality (instead of a simple casual or placebo effect).
6. Antimitotic therapy
6.1 Bleomycin
Bleomycin is a chemotherapeutic agent which has an antitumor, antibacterial and 
antiviral activity which may be related to its ability to bind with deoxyribonucleic acid 
(DNA), causing bleomycin strand scission and elimination of pyrimidine and purine 
bases [116]. It selectively affects squamous cell and reticuloendothelial tissue [117]. 
Bleomycin is not thought to bind directly to HPV [10]. Bleomycin causes acute tissue 
necrosis that may stimulate an immune response, as evidenced by the fact that it is less 
effective as a wart treatment in immunosuppressed renal transplant patients [118–121].
Adverse effects include injection pain and burning, erythema, swelling and pain 
within 24–72 h after injection before a black thrombotic eschar forms. Local compli-
cations after periungual injections are nail loss [122] or dystrophy [123]. Reynaud’s 
phenomenon in treated fingers, local pigmentation [124] or urticaria [122], even 
flagellate hyperpigmentation [125] are reported after.
In a systemic review [126], comparing intralesional bleomycin with placebo, 
the studies have given conflicting results. Intralesional bleomycin was compared 
with saline or sesame oil; duration was 6 weeks to 3 months. The RCTs in the review 
favour I/L Bleomycin, and only one study opined placebo to be more effective. The 
result of wart clearance was between 18 and 94%, but the study showed clear-
ance rate to be 94%, which was not significantly different from the result (73%) 
achieved by placebo injections of saline. Concentration of 0.5% bleomycin is more 
effective than concentration of 0.25% or 1% bleomycin. Pain was experienced by 
most patients, irrespective of doses. In a study of comparison between intralesional 
Bleomycin and cryotherapy, 0.1% concentration of bleomycin was used [127]. 
Greater efficacy in clearing warts was shown with intralesional bleomycin than in 
cryotherapy. The clearance rates of warts for intralesional bleomycin therapy found 
were 97%, and in 94.9% of patients, all warts treated with bleomycin were cleared. 
There was significantly less number of treatment sessions, with a mean of 1.38 in 
case of bleomycin treatment than the cryotherapy where the mean is 3.08.
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6.2 Podophyllotoxin
Podophyllotoxin is a topical antimitotic that is purified from the plant fami-
lies Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum) 
or can be synthesised chemically. It is the active agent of podophyllin resin 
and is available as a 0.5% solution. Podophyllotoxin binds to microtubules and 
causes mitotic arrest in the metaphase of cell division [128]. Treatment should 
be limited to no more than 10 cm2 of wart tissue, and no more than 0.5 mL/day 
of solution should be given. This is a patient-applied therapy. Podophyllin is a 
non-standardised unstable plant extract, derived from may apple (Podophyllum 
peltatum Linné), and contains the active agent podophyllotoxin. American 
Podophyllum contains one fourth the amount of podophyllotoxin than Indian 
Podophyllum does. The potency of podophyllin varies considerably between 
batches. The exact mechanism of action is unknown. Since it tends to work better 
on mucosal surfaces, it is used primarily to treat genital warts. Little informa-
tion is available regarding treatment of non-genital warts with this medication. 
A single topical application of podophyllin cures less than one third of patients 
with genital warts [129, 130].
It results in necrosis when applied to anogenital warts. Only a trained medical 
professional can apply it, and it cannot be dispensed to a patient. CDC guidelines 
for anogenital warts, recommended regimens for External Anogenital Warts (i.e. 
penis, groin, scrotum, vulva, perineum, external anus and perianus), includes 
patient-applied therapy with podofilox (podophyllotoxin) 0.5% solution or 
gel—using a cotton swab or finger. This podofilox solution (using a cotton swab) 
or gel (using a finger) should be applied to anogenital warts twice daily for 3 
consecutive days, followed by 4 days of drug interval. If necessary, it can be 
repeated, for up to four cycles. The total treated area should not exceed 10 cm2,  
and up to 0.5 ml podofilox should be used per day [131]. If possible initial 
application should be demonstrated by one healthcare provider for demonstra-
tion of proper application and technique and to identify the appropriate warts 
for treatment. Mild to moderate pain or local irritation might develop after 
 treatment [131].
Podophyllotoxin, the active ingredients of podophyllin, is contraindicated 
in pregnancy. Though human data not available during application in lactating 
mother, it is considered as potential toxic. Podophylline, a raw form, is also con-
traindicated in pregnancy and breastfeeding mother, due to the potential severe 
myelotoxicity and neurotoxicity in the mother, though no human data available. 
The American college of Obstetricians and Gynecologists and other sources con-
traindicated the use of podophyllum agents include the use of podophyllotoxin 
(podofilox) during pregnancy and in the vagina or cervix at any time [132]. In a 
randomised comparative study, 60 women with genital warts were treated with 
either weekly application of 20% podophyllin solution or self-treatment with 0.5% 
podophyllotoxin cream twice daily for 3 days in weekly intervals. Patients were 
treated for a maximum of four treatment cycles, and final assessment was carried 
out after 3 months. Podophyllotoxin cream had a significantly better clearance 
than podophyllin solution, a primary clearance of was 82% vs 59%. These final 
clearance decreased to 71% and 48% at the 3-month follow-up, respectively. Total 
wart clearance was 94% with podophyllotoxin and 74% with podophyllin solution. 
Podophyllin cream came to as easy to apply and effects significantly better than 
podophyllin solution. Local side effects were mild to moderate with erythema, and 
erosion appeared to be higher in the podophyllotoxin group but not so serious to 
discontinue treatment [133].
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7. Immunotherapy
This treatment uses the patient’s own immune system to fight the warts. Some 
types of immunotherapy only target certain cells of the immune system. Others 
affect the immune system in general. Because of the cumbersome nature of the 
conventional procedures and a high risk of recurrence, immunotherapy is becoming 
more and more popular, especially in the treatment of refractory cutaneous and 
genital warts. These include various topical, intralesional and systemic agents. There 
are no well-defined criteria or consensus on when immunotherapy should be tried in 
a patient with warts. Current indications [134] include the following (Table 1).
1. Recalcitrant warts
2. Recurrent warts
3. Extensive warts
4. Difficult-to-treat areas—periungual and palmoplantar sites
7.1 Imiquimod
Imiquimod is a non-nucleoside heterocyclic amine which acts as an immune 
response modifier that may stimulate cytokines, including interferon-α, inter-
leukin-1, interleukin-6, tumour necrosis factor-α, granulocyte-macrophage 
colony-stimulating factor and granulocyte colony-stimulating factor [135]. In a 
quantitative systemic review of published randomised control trials, six RCTs were 
evaluated, and all six studies were conducted in the sitting of home administration 
Courtesy of Prof Devinder M Thappa and Minu J Chiramel [134].
Table 1. 
Various agents used in immunotherapy of warts.
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after initial professional examination and advice wart locations are genital, both in 
males and females. Five of the studies are on immunocompetent patients and one 
study on HIV-positive patients; 90% of the study population are male. Imiquimod 
was used as 5% cream in 4 trials and 2% cream in one trial, with complete clearance 
achieved in 51% in imiquimod group but only 6% patients in placebo group. The 
number needed to treat (NNT) was 2.2 (95% confidence interval 2.0–2.6). At least 
50% reduction in wart area occurred in 72% of patients treated with Imiquimod 
5% cream and 20% in placebo treated group. The number needed to treat was 1.9 
(1.7–2.2). Warts were completely cured and did not recur in 37% (31% to 43%) 
of patients treated with imiquimod 5%, and 4% (2% to 6%) of patients treated 
with placebo. The NNT was 3.0 (2.5 to 3.8). Fewer patients were cured with 1% 
imiquimod in two trials, and for this concentration the NNT was 9.5 (5.9 to 25). 
Imiquimod 5% cream was significantly more effective than imiquimod 1% cream 
for complete wart clearance [136]. Common adverse events were localised itching, 
erythema, burning and erosion or excoriation, there was rarely any withdrawal 
from study due to these adverse effects. In HIV infected patients with warts, at least 
50% reduction of wart area was seen in 38%, and in placebo it was 14%. Adverse 
events were similar to non-HIV group [137]. It is found to be effective and safe in 
children and there are reports of safe use in pregnancy [138, 139]. Disadvantages of 
using imiquimod 5% cream were the high cost and the length of average treatment 
(9.5 weeks).
7.2 Mycobacterium w
Mycobacterium indicus pranii or Mycobacterium w is rapid growing nontuber-
cular mycobacteria, which has been found to induce a strong pro-inflammatory 
response while injected intralesionally. There is a prominent delayed hypersensitiv-
ity response, leading to clearance of warts both at the site of injection and distally 
[140]. The response varied by 54–93% in cutaneous warts and 89% in genital warts 
[140–143]. It is administered in two ways—either with an intradermal sensitising 
dose or without it. In the first method, a sensitising dose of 0.1 ml is administered 
intradermally in the deltoid region followed by 2–4 weekly intralesional injections 
in few warts (maximum 0.1 ml in each sitting) for up to 10 sittings. In the latter, 
the sensitization dose is missed, and direct intralesional injections are started [140, 
141]. Mycobacterium w vaccine came as equally efficacious in treatment of refrac-
tory extragenital warts in comparison with cryotherapy and Imiquimod, 5%,. Mw 
vaccine has an added advantage of clearance of distant warts and reduction of viral 
load [144, 145]. The reported side effects include pain, nodularity, ulceration, scar-
ring at the site of injection, flu-like symptoms, fever and lymphadenopathy [143]. 
Paraesthesia on the limb distal to the site of injection has also been reported [146].
7.3 Bacillus Calmette-Guérin vaccine
The delayed hypersensitivity response against the antigen is the key to clinical 
response against warts, same as that of the Mw vaccine. It increases the serum levels 
of IL-12 and decreases the level of IL-4 [147]. One to three doses are administered 
1 month apart. In cutaneous warts (common, plantar, and plane warts), there was 
a resolution rate of 39.7% [148]. Topically applied BCG paste (weekly for 6 weeks) 
has also been found to be effective in children with common warts and plane warts 
with 65% resolution [149], and usually there are no side effects. However, another 
report in India showed a high incidence of flu-like symptoms precluding further 
doses in 57% of patients, making one question its safety in tuberculosis endemic 
countries like India [150].
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7.4 MMR vaccine, Candida, Trichophyton and tuberculin antigens
Various types of vaccines and antigens were tried for wart management. 
Measles, mumps and rubella (MMR) viral vaccine accelerates the clearance of 
virus and viral infected cells by stimulation of cell-mediated and humoral immu-
nity [151]. In this double-blind RCT, MMR vaccine was tried for three injections 
in 2-week interval with normal saline as control; 75% of patients had complete 
clearance, and another 16.6% had more than 50% clearance. There were no side 
effects, and in 6-month follow-up, there was no relapse [151]. In another study 
of MMR vaccine, 81.4% of patients had complete clearance; another 10% had 
partial clearance, in comparison to 27.5% and 15% with saline control [152]. A 
preliminary, open-label (PPD: purified protein derivative) study to investigate 
the effectiveness of the tuberculin antigen in the treatment of recalcitrant warts, 
taking advantage of the vaccination schedule in their country was designed. Three 
consecutive intralesional tuberculin (5TU PPD RT23-tween 80 solution) injections 
with 3-week intervals into each target wart, depending on the tuberculin reactivity, 
were performed. Injections of 0.3, 0.2 and 0.1 mL of antigen were administered 
to patients with indurations of 5–9, 10–15 and > 15 mm, respectively. Five patients 
(29.4%) demonstrated complete clearance, five (29.4%) had partial and five 
(29.4%) minimal response. Some patients showed complete clearance of untreated 
facial warts also. Patients with initial PPD test site in duration less than 10 mm had 
no or minimal response [153]. Mumps and Candida antigen injection in paediatric 
age group with recalcitrant warts had 47% complete resolution, and 13% had 
partial resolution. Injections were given in three weekly intervals, and an average 
of 3.87 injections was given. Patients with initial high response to skin antigen 
test shows excellent result [154]. Injection with mumps, Candida or Trichophyton 
antigen, alone or in combination, is given in 3-week interval, up to 10 injections. In 
patients who have completed the study, 50% had complete clearance, and the other 
50% had 75–90% clearance. Local erythema and oedema were the only side effects, 
in 30% of patients. Patients who had complete clearance had clearance also in their 
distant verruca lesions [155]. Candida albicans intralesional immunotherapy in 
single also came as safe, well tolerated and suitable for multiple warts of hand and 
fingers, plantar warts and recalcitrant warts, even in non-injected warts [156]. In a 
randomised, single blinded, placebo-controlled large study of mumps, Candida and 
Trichophyton antigen, with or without interferon α 2b, 41% of patients with antigen 
alone, 57% antigen and interferon and 9% in only interferon had complete clear-
ance in comparison to 19% only in the normal saline group [157]. The combination 
of mumps, Candida and Trichophyton also came to be effective as 74% of patients 
responded to test antigen had complete clearance with significant number also 
showing resolution of untreated distant warts [158]. Response of other studies with 
Candida antigen varied as 72% [159], 74% [160], 85% [161], 56% [162] and 87% 
[163], indicating antigen therapy in wart is a good hope for target and distant wart 
lesions with minimum side effects.
7.5 Interferons
Interferon has been shown to be active against HPV both in vitro and in vivo, to 
protect murine cells against infection with bovine papillomaviruses and to elimi-
nate extrachromosomal viral DNA from infected cells [164, 165]. In a systematic 
meta-analysis, the rate of complete response in locally used interferon was 44.4% 
in comparison to placebo, 16.1%. The complete response rate of systemically used 
interferon as compared to placebo for treating genital warts had no perceivable 
discrepancy, for systemically used interferon 27.4% and placebo 26.4%. Both groups 
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had near same recurrence rate (interferon 21.1% vs. placebo 34.2%, p > 0.05). In 
subgroup analysis, it was noticed that relapse was less in intralesional interferon in 
comparison to placebo group, but relapse rate were the same in between systemic 
and placebo groups. Adverse events were mostly mild and transient and could be 
tolerated [166].
7.6 Zinc
Dietary zinc has profound effects on the human immune system and deficiency 
leads to reduced immune capacity [167, 168]. It can be given as topical preparation, 
oral medication or intralesional. Topical preparation as 10% zinc sulphate lotion 
yields complete clearance in 80% in plane wart [169]; plane warts were seen in 
85.7% [170]. Complete clearance noticed in 61% patients after 1 month therapy and 
87% after 2 months of therapy with oral zinc sulphate 10 mg/kg/day in a placebo-
controlled trial [171]. But it was not the same in other studies, 50% complete 
clearance with the same dose after 2 months in another open level clinical study 
[172]. Intralesional 2% zinc sulphate too has been found to induce clearance of 
warts [173].
7.7 H2 receptor blockers
H2 blockers, such as cimetidine and ranitidine, have been tried in treatment of 
warts. They block the type 2 histamine receptors on suppressor T cells and aug-
ment cell-mediated immunity [174]. It increases the levels of IFNγ and IL-2 and 
decreases the levels of IL-18 [175]. It has been used in a dose of 20–40 mg/kg/day 
for 3–4 months with response rate ranging from 30 to 87% [176, 177]. There is no 
significant difference between cimetidine and placebo [178], and some author 
proposed a placebo effect for cimetidine [179].
7.8 Levamisole
Levamisole, an antihelminthic agent, is found to have immunomodulatory 
effects, making it effective in various dermatological disorders including viral warts 
at a dose of 2.5–5 mg/kg/day for 3 consecutive days every 2 weeks for 4–5 months 
[180–182]. The response to levamisole was approximately 60%. Side effects are 
rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia and a flu-like 
syndrome and rarely cause myopathy, leukocytoclastic vasculitis, lichenoid erup-
tions and leukoencephalopathy [183, 184].
7.9 HPV vaccines
Since 2006, two vaccines against Human papillomavirus (HPV) have been 
licenced in more than 100 countries [185]. Both vaccines target HPV types 16 and 
18, which account for about 70% of all cervical cancer cases, and the quadrivalent 
vaccine also targets HPV types 6 and 11, associated with 90% of genital warts (GWs) 
[186]. In Denmark, the quadrivalent HPV vaccine was introduced into the children’s 
vaccination programme in January 2009 for 12-year-old girls. In 2014 the European 
Medicines Agency and the World Health Organisation Strategic Advisory Group of 
Experts recommended a two-dose schedule for 9–13-year-old girls. However, three-
dose schedule offers better protection against genital warts than a two-dose schedule 
in a nationwide study. But, if the dosing interval extends (about six months), the 
two dose schedule came as effective as three. The quadrivalent HPV vaccine that 
comprises the L1 protein of HPV types 6, 11, 16 and 18 has been in use on a large scale 
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in countries like Denmark with a decline in the prevalence of genital warts [187]. 
Similar decline in genital warts has been noticed in the UK and Australia [188, 189].
7.10 Autoimplantation therapy
Autowart inoculation by means of homologous autoimplantation helping to 
induce specific cell-mediated immunity has been proposed as a treatment option for 
recalcitrant, extensive and genital wart [190]. About 83 patients with all types of 
wart lesions were included in a study. At 16 weeks of therapy, 69.5% of patients recov-
ered completely, and more than 75% improvement occurred in another 8.5% patients. 
No significant complication was documented. There was no recurrence within study 
period [191]. Another study also had noticed 73.3% total clearance of warts, with a 
majority of them (91%) within 2 months [190]. Inoculation site infection and post-
inflammatory hyperpigmentation and hypopigmentation are the side effects.
7.11 Contact sensitizers
Contact sensitizers are a mode of inducing a type IV hypersensitivity reaction, 
thus making them a form of topical immunotherapy [28]. Diphencyprone (DCP) 
is the preferred compound. DCP 2% solution is applied after every 10–14 days, 
on the medial side of upper arm—till there is appearance of local erythema and 
vesiculation—and this may be repeated up to three times. Warts were then first 
pared followed by application with stepwise concentration of DCP: 0.01, 0.05, 0.10, 
0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0 and 6.0%. Treatments are applied every 1–4 weeks. 
Resistant palmoplantar warts treated with DCP over 8 years [192] exhibited 88% 
clearance rate. However, a large percentage of patients developed adverse effects 
(56%), including painful blistering at the site of sensitization and near warts, 
pompholyx-like or generalised eczematous eruption, influenza-like symptoms, 
vesiculation elsewhere due to passive transfer of DCP and inguinal lymphadenopa-
thy. They concluded that patients with recalcitrant palmar, plantar, periungual and 
digital warts are good candidates for DCP therapy [193].
8. Others
There are various other agents being tried infrequently in the management of 
warts.
Historic folk remedies have included many variants.
Duct tape occlusion therapy involves placing a piece of duct tape over the wart. 
The mechanism of action of this technique still remains unknown [194].
Components of garlic (Allium sativum) have been shown to have antiviral activ-
ity and to inhibit cellular proliferation of virally infected cells, resulting clearance of 
wart with less recurrence [195].
Application of paste made of baking powder and castor oil is age old technique 
for warts.
Herbal preparations such as Echinacea and propolis are reported to boost 
the immunity when administered orally [196], act as immunomodulators and 
improve warts.
Sinecatechins are derived from green tea extract (Camellia sinensis) and are 
marketed as a 10% ointment, containing around eight catechins. A clearance rate of 
46–52% has been noticed in various studies [197].
Glycyrrhizic acid, obtained from the root of Glycyrrhiza glabra, has anti-
viral, anti-inflammatory and antiulcerative properties. When used with an 
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immunostimulant [198], it was shown to have a slightly better efficacy than 
podophyllin (87%). The glycyrrhizic acid is a safe and effective treatment for the 
management of anogenital warts during pregnancy [199].
Intralesional injection of 0.2 ml of 15 mg/kg vitamin D3 led to complete reso-
lution [200] in 19 (82.60%) out of 23 patients with palmoplantar warts and 14 
(77.77%) of 18 patients with verruca vulgaris.
9. Conclusion
Numerous varieties of approaches for wart management are there. It is difficult 
to choose the best wart treatment. It should be determined by type of wart, whether 
old or new; site; immune status of the patient; pregnancy; the effects and side 
effects of the wart management procedure; its compliance with patient; and above 
all the availability of the planned modality of treatment. A rational consideration of 
all factors can provide an appreciable benefit.
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